

# CANCER SCIENCE INSTITUTE OF SINGAPORE IN THE SPOTLIGHT

ISSUE 68 | SEP 2019

## IN THIS ISSUE

New High-throughput Screen Identifies Compounds That Reduce Viability in Liver Cancer Cells

Targeting Jak/Stat Pathway as a Therapeutic Strategy for HCC

CAV1 - GLUT3 Signaling is Important for Cellular Energy and Can Be Targeted by Atorvastatin in NSCLC

CSI Deputy Director, Prof. Goh Boon Cher Receives National Outstanding Clinician Scientist Award

## UPCOMING EVENTS

CSI Seminar  
Francesco Ferrari  
1 Oct 2019

RNA Biology Symposium  
2019  
3 - 4 Oct 2019

CSI Research Meeting  
11 Oct 2019

CSI Seminar  
Lucy A. Godley  
14 Oct 2019

RNA Club  
28 Oct 2019


**New High-throughput Screen Identifies Compounds That Reduce Viability Specifically in Liver Cancer Cells That Express High Levels of SALL4 by Inhibiting Oxidative Phosphorylation. (Gastroenterology, Aug 2019)**

The aberrant expression of transcription factor SALL4 has been reported in many solid tumor and leukemia cells. In this study led by Prof. Daniel Tenen, Dr. Tam Wai Leong and Dr. Justin Tan, the group identified compounds that selectively reduce the viability of SALL4 cells. By developing a stringent high-throughput screening platform, they discovered inhibitors of oxidative phosphorylation, which impede the growth of xenograft tumors from SALL4hi cells in mice. These inhibitors could be a potential avenue for therapeutic treatments for liver tumors with high levels of SALL4.



**Targeting Jak/Stat Pathway as a Therapeutic Strategy against SP/CD44+ Tumorigenic Cells in Akt/ $\beta$ -catenin-driven Hepatocellular Carcinoma. (J Hepatol, Sep 2019)**

The high incidence of hepatocellular carcinoma (HCC) in Asian countries underscores the need for new therapeutic targets to improve existing treatment modalities. Recent study helmed by A/Prof. Edward Chow and his team elucidated the potential use of Jak/Stat inhibitors for the treatment of advanced liver cancer. Results revealed that Jak/Stat inhibitors were able to effectively mitigate tumour proliferation and formation in liver cancer. Findings from this study reveal a potential therapeutic intervention that could hold key to treating HCC.



**CAV1 - GLUT3 Signaling is Important for Cellular Energy and Can Be Targeted by Atorvastatin in Non-Small Cell Lung Cancer. (Theranostics, Aug 2019)**

Research group helmed by Dr. Chin Tan Min, Dr. Azhar Ali and Prof. Daniel Tenen was involved in an engaging study that found links between elevated cellular cholesterol and TKI-resistance in non-small cell lung cancer (NSCLC). By investigating the anti-tumoural properties of Atorvastatin, the team uncovered a mechanism by which Atorvastatin inhibits Cav1 expression, thereby suppressing the growth of TKI-resistant NSCLC. Results from this study provide the rationale and therapeutic merits of statins in the treatment of NSCLC.



## AWARDS & ACHIEVEMENTS

**CSI Deputy Director, Prof. Goh Boon Cher, Receives National Outstanding Clinician Scientist Award**

CSI extends our heartiest congratulations to our Deputy Director, Prof. Goh Boon Cher, for being awarded the National Outstanding Clinician Scientist Award at this year's National Medical Excellence Awards (NMEA) ceremony. The NMEA is a national-level award to recognize the efforts of clinicians, clinician-scientists and other healthcare professionals for their contributions.

